Allergan Inc


  • --We based our opinion of AEGON's primary servicing operation on the company's long, successful track record servicing multifamily/commercial real estate loans primarily originated for life insurance companies, experienced management team, good leverage of technology, and sound control environment.

  • *Comments on order regarding permanent injunction against Merz Pharmaceuticals. *Order restricts Merz Pharmaceuticals' ability to sell& solicit purchases of. Xeomin to remain in place until November 1,2012.

  • --We have reviewed Saecure 8 NHG and Saecure 9 as part of our surveillance review cycle. --Arrears levels are low and the level of credit enhancement has increased for all classes of notes in both transactions, due to deleveraging. Standard& Poor's Ratings Services today affirmed its credit ratings on all classes notes in Saecure 8 NHG B.V. and Saecure 9 B.V..

  • Botox Boom or Bust?     Wednesday, 2 May 2012 | 2:36 PM ET

    David Pyott, Allergan president and CEO discusses his company's 2012 outlook and the Botox market.

  • The Trade Behind Allergan's Pullback, Cramer     Thursday, 12 Apr 2012 | 6:25 PM ET

    Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.

  • Allergan CEO on Botox Expansion     Wednesday, 28 Mar 2012 | 3:40 PM ET

    Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.

  • Will Allergan Raise It's Guidance?     Wednesday, 26 Oct 2011 | 6:50 PM ET

    David Pyott, Allergan chairman/CEO, discusses the company's earnings, and products in the big pharma pipeline, with Mad Money's Jim Cramer.

  • Botox: Behind the Wrinkles     Monday, 12 Sep 2011 | 4:35 PM ET

    Allergan is finding ways to deliver returns for investors in a struggling market and discussing business strategies behind the brand, with David Pyott, Allergan chairman/CEO.

  • Allergan Grows on Product Strategy     Wednesday, 3 Aug 2011 | 6:55 PM ET

    Mad Money host Jim Cramer explains why Allergan isn't about to fall off a patent cliff like so many other big pharma companies. David Pyott, Allergan chairman, president & CEO weighs in on the company's earnings.

  • Weighing the Cost of Obesity     Friday, 24 Jun 2011 | 11:24 AM ET

    Making a case for lap-band surgery and discussing the benefits to patients and insurance companies, with David Pyott, Allergan CEO.

  • Allergan CEO Talks Earnings     Monday, 23 May 2011 | 6:15 PM ET

    David Pyott, Allergan chairman & CEO, discusses earnings and the aesthetics business, including Botox.

  • Allergan's Plumped-Up Outlook     Monday, 9 May 2011 | 7:14 AM ET

    Insight on why the Botox-maker is raising its full-year sales and earnings outlook, with David Pyott, Allergan chairman/CEO.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.